In the past week, CNMD stock has gone up by 3.51%, with a monthly gain of 14.55% and a quarterly surge of 5.01%. The volatility ratio for the week is 4.23%, and the volatility levels for the last 30 days are 3.51% for Conmed Corp. The simple moving average for the past 20 days is 8.63% for CNMD’s stock, with a -5.76% simple moving average for the past 200 days.
Is It Worth Investing in Conmed Corp. (NYSE: CNMD) Right Now?
Conmed Corp. (NYSE: CNMD) has a price-to-earnings ratio that is above its average at 24.47x. The stock has a 36-month beta value of 1.46. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CNMD is 29.95M, and at present, short sellers hold a 10.86% of that float. On September 13, 2024, the average trading volume of CNMD was 423.39K shares.
CNMD) stock’s latest price update
Conmed Corp. (NYSE: CNMD)’s stock price has gone rise by 4.92 in comparison to its previous close of 73.31, however, the company has experienced a 3.51% increase in its stock price over the last five trading days. globenewswire.com reported 2024-09-12 that Dublin, Sept. 12, 2024 (GLOBE NEWSWIRE) — The “Carpal Tunnel Release Systems – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. The global market for Carpal Tunnel Release Systems was estimated at US$604.4 Million in 2023, and is projected to reach US$809.7 Million by 2030, growing at a CAGR of 4.3% from 2023 to 2030. The growth in the carpal tunnel release systems market is driven by several factors, including technological advancements, an increase in the prevalence of conditions requiring such interventions, and heightened patient preference for minimally invasive procedures. The continuous development of new technologies such as enhanced endoscopic equipment and improved surgical techniques contributes significantly to the efficacy and safety of carpal tunnel surgeries, appealing to both surgeons and patients.
Analysts’ Opinion of CNMD
Many brokerage firms have already submitted their reports for CNMD stocks, with Needham repeating the rating for CNMD by listing it as a “Buy.” The predicted price for CNMD in the upcoming period, according to Needham is $129 based on the research report published on February 01, 2024 of the current year 2024.
CL King, on the other hand, stated in their research note that they expect to see CNMD reach a price target of $140. The rating they have provided for CNMD stocks is “Buy” according to the report published on May 22nd, 2023.
KeyBanc Capital Markets gave a rating of “Overweight” to CNMD, setting the target price at $124 in the report published on March 27th of the previous year.
CNMD Trading at 10.69% from the 50-Day Moving Average
After a stumble in the market that brought CNMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.41% of loss for the given period.
Volatility was left at 3.51%, however, over the last 30 days, the volatility rate increased by 4.23%, as shares surge +14.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.74% upper at present.
During the last 5 trading sessions, CNMD rose by +3.51%, which changed the moving average for the period of 200-days by -29.31% in comparison to the 20-day moving average, which settled at $71.30. In addition, Conmed Corp. saw -29.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNMD starting from Peters Stanley W III, who proposed sale 2,171 shares at the price of $72.40 back on Aug 27 ’24. After this action, Peters Stanley W III now owns shares of Conmed Corp., valued at $157,181 using the latest closing price.
Peters Stanley W III, the President AS and AET of Conmed Corp., sale 4,000 shares at $71.82 during a trade that took place back on Jun 14 ’24, which means that Peters Stanley W III is holding 63 shares at $287,280 based on the most recent closing price.
Stock Fundamentals for CNMD
Current profitability levels for the company are sitting at:
- 0.12 for the present operating margin
- 0.54 for the gross margin
The net margin for Conmed Corp. stands at 0.08. The total capital return value is set at 0.08. Equity return is now at value 11.86, with 4.28 for asset returns.
Based on Conmed Corp. (CNMD), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at 0.18. The debt to equity ratio resting at 1.1. The interest coverage ratio of the stock is 3.95.
Currently, EBITDA for the company is 182.19 million with net debt to EBITDA at 4.78. When we switch over and look at the enterprise to sales, we see a ratio of 2.6. The receivables turnover for the company is 5.33for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.34.
Conclusion
To sum up, Conmed Corp. (CNMD) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
